Stockscreener 앱 받기
106.21
0.92%
0.97
Incyte Corp 주식(INCY)의 최신 뉴스
New Incyte Drug Combo Shows Power Against Deadly Lymphoma - MyChesCo
EC approves label expansion of INCY's lymphoma drug Minjuvi - MSN
Why Incyte (INCY) Stock Is Trading Up Today - Finviz
Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain? - Yahoo Finance
Incyte (INCY) Receives Updated Buy Rating from TD Cowen | INCY S - GuruFocus
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Earnings Preview: What To Expect From Incyte's Report - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH) - The Globe and Mail
Lobbying Update: $70,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Finviz
Incyte Corporation (INCY) Stock Analysis: Strong Revenue Growth and Strategic Developments in the Biotech Sector - DirectorsTalk Interviews
Incyte Corp. stock underperforms Monday when compared to competitors - MSN
ImmunityBio, Xencor Drugs Win E.U. Nods - Los Angeles Business Journal
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
What margin trends mean for Incyte Corporation stockOil Prices & High Return Trade Guides - Улправда
Incyte Corporation $INCY Stock Holdings Increased by Cerity Partners LLC - MarketBeat
Will Incyte Corporation (ICY) stock beat value stocks2025 Analyst Calls & Smart Investment Allocation Tips - ulpravda.ru
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Incyte jumps amid takeover speculation - MSN
Bull of the Day: Eli Lilly (LLY) - Finviz
Can Incyte Corporation stock reach $100 price targetExit Point & Scalable Portfolio Growth Methods - ulpravda.ru
Why Incyte Corporation (ICY) stock is a strong buy callGap Down & Expert Approved Momentum Ideas - ulpravda.ru
Can Incyte Corporation stock beat market expectations this quarter2025 Macro Impact & Low Volatility Stock Recommendations - ulpravda.ru
Can Incyte Corporation stock hit analyst price targets2025 Key Lessons & Safe Entry Momentum Stock Tips - ulpravda.ru
Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL - Yahoo Finance
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp EVP & Chief Medical Officer Sells 15,634 Shares - TradingView — Track All Markets
Incyte (INCY) Stock Is Up, What You Need To Know - Finviz
Incyte (NASDAQ:INCY) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma - Indian Pharma Post
Incyte stock hits 52-week high at $109.38 - Investing.com
Incyte Corp. (NASDAQ:INCY) Emerges as a Compelling Value Stock with Strong Fundamentals - Chartmill
INCY: Morgan Stanley Boosts Price Target to $94 in Latest Analys - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Dow, S&P 500 Hit Record Highs; Guardant, Intuitive Surgical, Incyte In Focus - Investor's Business Daily
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins (NASDAQ:INCY) - Seeking Alpha
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma - Finviz
Incyte's Monjuvi poised for first-line DLBCL expansion after pivotal study win - FirstWord Pharma
Incyte (NASDAQ:INCY) Price Target Raised to $94.00 - MarketBeat
Incyte reports positive results in late stage trial of lymphoma drug - Delaware Business Now
Positive top-line results for Incyte’s tafasitamab in DLBCL - The Pharma Letter
Spotlight On: Incyte's win in first-line DLBCL points to incremental growth opportunity for Monjuvi - FirstWord Pharma
Incyte stock rises as Stifel reiterates Buy rating on positive trial data - Investing.com India
Why Is Incyte Stock Gaining Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's blood cancer therapy slows disease progression in trial - Reuters
The Bull Case For Incyte (INCY) Could Change Following Positive frontMIND Phase 3 DLBCL Results - simplywall.st
Incyte (INCY) Achieves Phase 3 Success with Tafasitamab in Lymph - GuruFocus
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com - Investing.com Canada
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma - BioSpace
Incyte (INCY) Achieves Key Milestones in Phase 3 Lymphoma Study - GuruFocus
Incyte’s tafasitamab meets primary endpoint in frontMIND trial - Investing.com
Incyte Corp (NASDAQ:INCY) Shows High-Growth Momentum and Strong Technical Trend - Chartmill
Financiere des Professionnels Fonds d investissement inc. Invests $1.48 Million in Incyte Corporation $INCY - MarketBeat
4.73%
2.76%
자본화:
|
볼륨(24시간):